-
Kelun Pharma’s Generic Jardiance Gains New Indication in China
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China for its generic version of BI/Eli Lilly’s Jardiance (empagliflozin). The hypoglycemic agent can now be used to reduce the risk of hospitalization due to heart failure in adult patients with symptomatic chronic heart failure. Jardiance:…
-
Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection
•
Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership with Fudan University Shanghai Cancer Center. The RMB 31 million (USD 4.5 million) deal will see the two Chinese entities collaborate on the translation of “breast cancer multi-gene detection” technology, marking a significant step forward…
-
By-Health Partners with Meituan’s Drug Purchase APP for New Retail Expansion
•
China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug purchase APP, a leading delivery platform in China. The collaboration aims to leverage the respective strengths of both companies to delve deeper into the new retail sector, focusing on innovation and digital transformation. Expanding Product…
-
Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with a local company in Pakistan. The collaboration aims to work together on the regulatory filing, distribution, and licensing of Kangtai’s 13-valent and 23-valent pneumonia vaccines in the Pakistani market. Pakistan’s Vaccination Plan and Market OpportunityPakistan,…
-
Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion
•
Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100 million (USD 14.54 million) in a Series A+ financing round. The round was led by Silicon Paradise Asset Management, with additional investments from DT Capital Partners and Qianzhan Investment. The proceeds will be used to…
-
NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis
•
The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s Category 1 drug, keverprazan, for the treatment of duodenal ulcers and reflux esophagitis in China. This approval marks a significant advancement in the treatment options available for these gastrointestinal conditions. Keverprazan: A New Potassium Competitive…
-
Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines
•
US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global revenues fell 7% year-on-year (YOY), but were up 1% when excluding foreign exchange effects, reaching USD 1.485 billion in Q4. Over the 12-month period, global revenues dipped 2% (or +4% excluding FX) to USD 6.2…
-
WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services
•
China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed Baidu’s ERNIE Bot, the China-based internet giant’s answer to the current global phenomenon ChatGPT. This strategic move will enhance the company’s capabilities in the rare disease sector by leveraging Baidu’s leading intelligent conversation technology. Application…
-
Eppendorf to Start Construction on New Shanghai Production Site
•
Germany-based life sciences service provider Eppendorf is set to begin work on a new production site in Shanghai, China, according to a report from PharmaBiz.com. This expansion marks a significant strategic move for the company, aiming to strengthen its presence in the Chinese market. New Production Site DetailsEppendorf has signed…
-
InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement
•
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune diseases, has announced receiving a notification from US major Biogen (NASDAQ: BIIB) to terminate the licensing agreement for its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib. InnoCare regains all rights, including intellectual property, R&D, manufacturing, and…
-
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to initiate a Phase I clinical study for its mRNA vaccine against COVID-19 variants and a Phase III study for its mRNA vaccine against the COVID-19 prototype as a sequential booster. This marks a significant step…
-
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
•
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III CLEAR study for its picankibart (IBI112), a recombinant anti-interleukin 23p19 subunit (IL23p19) antibody injection, in moderate-to-severe plaque psoriasis. This marks a significant advancement in the development of innovative treatments for this chronic skin condition. Phase…
-
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
•
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical study for its in-house developed gene therapy FT-002. This marks a significant milestone in the development of treatments for X-linked retinitis pigmentosa (XLRP), a genetic disorder affecting vision. FT-002: First-in-Class Gene TherapyFT-002 is a recombinant…
-
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
•
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug Designation (ODD) from the US FDA for its Category 1 drug candidate KH617 in glioblastoma. This designation is a significant milestone in the development of KH617, which is aimed at treating advanced solid tumors and…
-
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
•
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase I clinical study for its Category 1 product BA2101. This marks it as the first long-acting anti-IL-4Rα monoclonal antibody to enter the clinical trial stage in China. BA2101 is being developed to treat allergic diseases…
-
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
•
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047, a potential first-in-class small-molecule degrader targeting BRD4, by Hangzhou-based Ranok Therapeutics Co., Ltd, has been accepted for review. This marks a significant step forward in the development of innovative cancer treatments. Discovery and Mechanism of…
-
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences Inc., (NASDAQ: CHRS) have announced positive findings from the final analysis of overall survival (OS) in the pivotal Phase III JUPITER-02 (NCT03581786) clinical study. The study assessed the programmed death-1 inhibitor Tuoyi (toripalimab) as a…
-
Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics
•
US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based Formosa Pharmaceuticals Inc., (TPE: 6838). The partnership aims to combine Eyenovia’s Optejet dispensing technology with Formosa’s unique APNT nanoparticle formulation platform, potentially leading to the development of new topical ophthalmic therapeutics that employ the Optejet…
-
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to carry out an open, multi-center Phase Ib/II clinical study for its injectable pipeline candidate SHR-A1921 combined with adebrelimab (SHR-1316) in advanced solid tumors. This marks a significant step in the development of…
